JBIO news

Jade Biosciences reported positive Phase 1 data for JADE101 and announced the start of a Phase 2 trial, bolstered by robust cash reserves expected to fund operations into late 2028.

Jade Biosciences, Inc. (JBIO) announced the appointment of veteran biopharmaceutical executive Dr. Mark Eisner to its board of directors. This leadership addition is expected to bolster the company's efforts in advancing its antibody-based autoimmune therapies.

Jade Biosciences held a conference call on June 1, 2026 to discuss interim Phase 1 data for JADE101, a clinical-stage therapeutic candidate. The company plans to advance to Phase 2 enrollment and potentially Phase 3 registrational studies pending positive results.